Press Release

Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance (LRA), today announced a pioneering funding mechanism to address one of the most common questions about lupus clinical care and management. The IDEAL (Investigate Dietary Approaches for Lupus) Initiative was established to fund pilot clinical studies assessing the impact of diet intervention on the lived experience … Lupus Therapeutics Announces a New, Groundbreaking Mechanism to Fund Clinical Studies Addressing the Impact of Diet, Nutrition, and Microbiome on Lupus

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3 PHOENYCS GO data reported by UCB and Biogen during ACR Convergence 2024. Study sponsors provided a detailed analysis of the pivotal trial to evaluate the efficacy and safety of dapirolizumab pegol (DZP) in patients with moderate-to-severe … Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data In Moderate-To-Severe Systemic Lupus

Two reports by Lupus Therapeutics, the clinical affiliate of the LRA, and the Lupus Clinical Investigators Network (LuCIN), on promoting equity in lupus clinical trials, and identifying trial barriers and solutions The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that 34 presentations, including research funded by the organization … Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support Nkarta in early … Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

The Lupus Research Alliance (LRA) is pleased to announce the appointment of Stacie J. Bell, PhD as Executive Vice President to lead Lupus Therapeutics (LT), the organization’s clinical research affiliate. An accomplished research scientist and organizational leader, Dr. Bell comes to Lupus Therapeutics with more than 25 years of experience in discovery research, clinical development, … Lupus Research Alliance Appoints New Executive Vice President of Affiliate Lupus Therapeutics

The Lupus Research Alliance and its affiliate Lupus Therapeutics will present data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus Studies (PALS), in increasing knowledge, perception, and intentions among people with Systemic Lupus Erythematosus (SLE) to participate in clinical trials. Results of … Promising Data Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these disparities for decades and now embarks on this highly … Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research